BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16683223)

  • 1. Modulating atherothrombosis: is there a place for vaccines in global prevention strategies?
    Becker RC
    J Thromb Thrombolysis; 2006 Jun; 21(3):285-6. PubMed ID: 16683223
    [No Abstract]   [Full Text] [Related]  

  • 2. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
    Sabatier B; Trinquart L; Emmerich J
    Arch Cardiovasc Dis; 2010 Oct; 103(10):497-501. PubMed ID: 21130962
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetic atherothrombosis: helpful adjunctive therapy.
    Chesebro JH
    Eur Heart J; 2008 Sep; 29(18):2191-2. PubMed ID: 18689803
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of negative interaction between use of β-blockers and statins on cardiovascular outcomes among patients with or at risk for atherothrombosis.
    Abtan J; Elbez Y; Bhatt DL; Steg PG
    J Am Coll Cardiol; 2014 Aug; 64(8):845-7. PubMed ID: 25145532
    [No Abstract]   [Full Text] [Related]  

  • 6. The proteomic approach in the development of prognostic biomarkers in atherothrombosis.
    Lorenzo O; Martín-Ventura JL; Blanco-Colio LM; Egido J; Tuñón J
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):25-30. PubMed ID: 19149703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population.
    Cederholm A; Frostegård J
    Ann N Y Acad Sci; 2007 Jun; 1108():96-103. PubMed ID: 17893975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Implications of the REACH registry for internal medicine].
    Ramos Salado JL
    Med Clin (Barc); 2009 Sep; 132 Suppl 2():34-7. PubMed ID: 19631837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-atherothrombogenic properties of PEDF.
    Yamagishi SI; Matsui T
    Curr Mol Med; 2010 Apr; 10(3):284-91. PubMed ID: 20236055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inflammation and atherothrombosis. Premature vascular injury. Diagnostic and therapeutic options for primary prevention].
    Ortiz Arduán A; Ruiz Ortega M; Cases Amenós A
    Nefrologia; 2008; 28 Suppl 3():23-7. PubMed ID: 19018734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous pulmonary thromboembolism and atherothrombosis: need for a new approach.
    Aursulesei V; Roca IC
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(3):724-32. PubMed ID: 25341292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics of patients with cerebrovascular disease in the REACH registry: the Spanish contribution.
    Suárez C;
    Cerebrovasc Dis; 2007; 24 Suppl 1():89-95. PubMed ID: 17971643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
    Kikano GE; Brown MT
    Mayo Clin Proc; 2007 May; 82(5):583-93. PubMed ID: 17511957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atherothrombosis: an excessively globalizing concept?].
    Castillo J; Blanco M
    Med Clin (Barc); 2009 Sep; 132 Suppl 2():2-4. PubMed ID: 19631830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of atherothrombotic disease (ATD).
    Feeman WE
    J Clin Lipidol; 2010; 4(2):136-7; author reply 137. PubMed ID: 21122642
    [No Abstract]   [Full Text] [Related]  

  • 16. The year in atherothrombosis.
    Sanz J; Moreno PR; Fuster V
    J Am Coll Cardiol; 2012 Sep; 60(10):932-42. PubMed ID: 22935466
    [No Abstract]   [Full Text] [Related]  

  • 17. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective.
    Santilli F; Davì G; Patrono C
    Vascul Pharmacol; 2016 Mar; 78():1-9. PubMed ID: 26111718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?].
    Badimón JJ; Santos-Gallego CG; Badimón L
    Rev Esp Cardiol; 2010 Jun; 63 Suppl 2():20-35. PubMed ID: 20540898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk factor control and treatment of atherothrombosis. Spain REACH Registry].
    Suárez C; Cairols M; Castillo J; Esmatjes E; Sala J; Llobet X; Palma JC;
    Med Clin (Barc); 2007 Oct; 129(12):446-50. PubMed ID: 17953908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Learning lessons from REACH.
    Kassianos GC
    Int J Clin Pract; 2007 Nov; 61(11):1786-8. PubMed ID: 17935542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.